|
|
|
|
|
Frovatriptan
drug data and news
Frovatriptan drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Frovatriptan | ||
| Brand Names/Synonyms | Frova; Frovatriptan; Miguard | ||
| Indication | For treatment of acute migraine headache in adults | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Frovatriptan is a selective 5-hydroxy-tryptamine1 (5-HT1B/1D) receptor subtype agonist, indicated for the acute treatment of migraine attacks with or without aura in adults. Frovatriptan is a 5-HT receptor agonist that binds with high affinity for 5-HT1B and 5-HT1D receptors. Frovatriptan has no significant effects on GABAA mediated channel activity and has no significant affinity for benzodiazepine binding sites. | ||
| Mechanism Of Action | Frovatriptan is believed to act on extracerebral, intracranial arteries and to inhibit excessive dilation of these vessels in migraine. Frovatriptan is a 5-HT receptor agonist that binds with high affinity for 5-HT1B and | ||
| Frovatriptan News (When available) |
Proposed acquisition of Cita Nov 18, 2005 Cita NeuroPharmaceuticals Inc. Accepts Offer by UK-Based Vernalis ... Nov 18, 2005 Vernalis raises £43m and buys Nov 18, 2005 Vernalis to buy Cita NeuroPharmaceuticals Nov 18, 2005 Vernalis Buys Cita for $64.5M Nov 18, 2005 Vernalis plc announces proposed acquisition of Cita ... Nov 18, 2005 Frovatriptan-Induced Hypomania Sep 24, 2005 Elan and UCB Announce Agreement to co-promote New Migraine Drug ... Oct 3, 2005 Vernalis interim losses increase Sep 22, 2005 Vernalis Reports Appointment of Piper Jaffray as Joint Broker Sep 22, 2005 Snap: Vernalis reaches migraine drug milestone Sep 6, 2005 Vernalis Trial Start Positive > VER.LN Aug 22, 2005 Vernalis Completes the Acquisition of the Privately Held UK ... Jul 26, 2005 Vernalis to Acquire the Privately Held UK Biotech Company Ionix ... Jul 6, 2005 Vernalis Reports Frovatriptan Interim Phase III Safety Data Jun 27, 2005 Vernalis to Acquire the Privately Held UK Biotech Company Ionix ... Jul 6, 2005 Vernalis Says Drug Is `Well Tolerated' for Menstrual Migraine Jun 26, 2005 Vernalis gets Frova trial boost Jun 27, 2005 Nomura Sees Room For Vernalis Upgrades Jun 27, 2005 TechMARK movers: Vernalis climbs, Medisys slides Jun 27, 2005 Vernalis Reports Frovatriptan Interim Phase III Safety Data 13 Sep 2002 Vernalis gets Frova trial boost 13 Sep 2002 Vernalis Says Drug Is `Well Tolerated' for Menstrual Migraine Jun 26, 2005 Head Off Migraines for Life May 31, 2005 Menstrual migraines cause pain, cost billions Apr 26, 2005 Entertainment ; Serena Williams miracle cure for migraine: Apr 17, 2005 Serena Williams Launches 'RALLY for Menstrual Migraine' Campaign ... Apr 12, 2005 Serena Williams Launches 'RALLY for Menstrual Migraine' Campaign ... Apr 12, 2005 Vernalis looks to raise £30m Mar 4, 2005 Triptan Nonresponder Studies: Implications for Clinical Practice Mar 7, 2005 Vernalis Exercises Option to Co-Promote Frova with Endo ... Feb 24, 2005 Smaller companies report: Thursday close Feb 24, 2005 Commercial law news - Allen + Overy advises Vernalis on placing ... Mar 1, 2005 | ||
| Dosage Forms | Not Available | ||
| Drug_Category | Anti-migraine Agents; Vasoconstrictor Agents; Anti-inflammatory Agents; | ||
| Absorption | The absolute bioavailability of an oral dose of frovatriptan 2.5 mg in healthy subjects is about 20% in males and 30% in females | ||
| Interactions |
-->Interactions for Frovatriptan: Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see CONTRAINDICATIONS). Concomitant use of other 5-HT1B/1D agonists within 24 hours of FROVA treatment is not recommended. Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists. If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised. Drug/Laboratory Test Interactions FROVA is not known to interfere with commonly employed clinical laboratory tests. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide | ||
| Chemical Formula | C14H17N3O | ||
| Molecular Weight | 243.304 g/mol | ||
| Smiles String | CNC1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 0.948 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Primarily hepatic. In vitro cytochrome P450 1A2 is the principal enzyme involved in the metabolism of frovatriptan | ||
| Half Life | 26 hours | ||
| Protein Binding [%] | ~15% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Frovatriptan.html http://www.rxlist.com/cgi/generic3/frova.htm http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/fro1622.shtml http://www.pharmgkb.org/views/index.jsp?objId= | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00270 | ||
| CAS Registry Number | 158930-17-7 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:7854164 | ||
| PharmGKB ID | PA10269 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |